Comparing two treatments for extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the efficacy and safety of a new treatment combination, BMS-986489 (which includes BMS-986012 and Nivolumab), with the standard treatment of Atezolizumab combined with Carboplatin and Etoposide for patients with extensive-stage small cell lung cancer. Participants will receive one of the two treatment regimens as their first-line therapy. The study will evaluate how well each treatment works and its safety profile in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
* Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
* Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Exclusion Criteria

* Participants have already received certain types of treatment for extensive stage small cell lung cancer
* Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

• Southern Cancer Center, PC
  Daphne, Alabama, United States Recruiting
• Florida Cancer Specialists - South
  Fort Myers, Florida, United States Recruiting
• Mid Florida Hematology and Oncology Center
  Orange City, Florida, United States Recruiting
• Florida Cancer Specialists - North
  St. Petersburg, Florida, United States Recruiting
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
  Marietta, Georgia, United States Recruiting
• Illinois Cancer Care
  Peoria, Illinois, United States Recruiting

+133 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• Testing valemetostat with atezolizumab for lung cancer treatment

  This study is testing a new combination of medications, valemetostat and atezolizumab, to see if it can safely help people with extensive-stage small cell lung cancer who have had some success with earlier treatments.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06807632

• Investigating BNT327 with chemotherapy for untreated small-cell lung cancer

  This study is testing whether a new treatment called BNT327, combined with standard chemotherapy, can help people with untreated extensive-stage small-cell lung cancer feel better compared to another treatment option.

  Recruiting at 188 sites Phase 3 BioNTech SE · Tucson, Arizona and 224 other locations · NCT06712355

• Evaluating a new treatment for extensive stage-small cell lung cancer

  This study is testing a new treatment combining ifinatamab deruxtecan and atezolizumab, with or without carboplatin, to see if it can help people with extensive stage-small cell lung cancer feel better and improve their treatment results.

  Recruiting at 55 sites Phase 1/2 Daiichi Sankyo · Birmingham, Alabama and 57 other locations · NCT06362252

• Combining Bevacizumab with Chemoimmunotherapy for Advanced Lung Cancer with Liver Metastases

  This study is testing whether adding a drug called bevacizumab to a combination of chemotherapy and another treatment can help people with advanced lung cancer that has spread to the liver live longer and feel better.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 2 other locations · NCT05588388

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.